Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis.
Boyce M, Moore AR, Sagatun L, Parsons BN, Varro A, Campbell F, Fossmark R, Waldum HL, Pritchard DM. [...]
Randomised trial of the effect of a gastrin/CCK2 receptor antagonist on esomeprazole-induced hypergastrinaemia: evidence against rebound hyperacidity.
Boyce M, van den Berg D, Mitchell T, Darwin K, Warrington S. Randomised trial of the effect [...]
The gastrin receptor antagonist netazepide (YF476) in patients with type 1 gastric enterochromaffin-like cell neuroendocrine tumours: review of long-term treatment.
Sagatun L, Mjønes P, Jianu CS, Boyce M, Waldum HL, Fossmark R. The gastrin receptor antagonist netazepide [...]
Potential clinical indications for a CCK2 receptor antagonist.
Boyce M, Lloyd KA and Pritchard DM. Potential clinical indications for a CCK2 receptor antagonist. Curr Opin [...]
Gastrin stimulates a cholecystokinin-2-receptor-expressing cardia progenitor cell and promotes progression of Barrett’s-like esophagus.
Lee Y, Urbanska AM, Wang H, Hayakawa Y, Au AS, Luna AM, Cheng W, Jin G, Bhagat [...]
Skeletal effects of a gastrin receptor antagonist in H+/K+ATPase beta subunit KO mice.
Aasarød K, Ramezanzadehkoldeh M , Shabestari M, Mosti M, Stunes A, Reseland J, Beisvåg V, Eriksen E, [...]